Department of Pharmaceutical Sciences, School of Pharmacy, North Dakota State University, Fargo, ND 58105, USA.
Int J Mol Sci. 2020 Nov 26;21(23):8989. doi: 10.3390/ijms21238989.
Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.
尽管在治疗方面取得了一些进展，但恶性皮肤黑色素瘤仍然是一种预后极差的癌症。新出现的证据表明，晚期糖基化终产物受体（RAGE）通过在癌细胞和基质细胞中的激活，在黑色素瘤的进展中起着关键作用。在肿瘤中，RAGE 的激活受到众多配体的驱动，S100B 和 HMGB1 最为显著，但许多其他配体的作用尚不清楚，也不应被低估。在这里，我们回顾了 RAGE 在黑色素瘤中的作用，并得出结论，靶向黑色素瘤中的 RAGE 可能是改善黑色素瘤患者预后的一种方法。
Zotero 插件
